Day: November 18, 2025

Nanterre, November 18th, 2025                       Disclosure of transactions in on shares from November 10th to November 14th,2025 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 17th, 2025, to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from November 10th to November 14th,2025: I – Aggregate presentation by day and by marketIssuer’s name Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares in Euro Market (MIC code)VINCI 10/11/2025 FR0000125486 2 864 116,292300 XPARVINCI 11/11/2025 FR0000125486 7 843 117,937700 XPARVINCI 11/11/2025 FR0000125486 61 118,150000 CEUXVINCI 11/11/2025 FR0000125486 787 117,450000 TQEXVINCI 12/11/2025 FR0000125486 18...

Aspo Plc  ANNOUNCEMENT  18.11.2025                Aspo Plc: Share repurchase 18.11.2025           In the Helsinki Stock Exchange             Trade date           18.11.2025    Bourse trade         Buy    Share                  ASPO    Amount             3 500 Shares  Average price/ share    6,7486 EUR  Total cost            23 620,10 EUR                Aspo Plc now holds a total of 30 243 shares    including the shares repurchased on 18.11.2025           The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.                On behalf of Aspo Plc             Nordea Bank Oyj                    Sami Huttunen Ilari Isomäki           For...

Company AnnouncementEPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In the Phase 3 EPCORE® FL-1 trial, fixed duration EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2, with approximately three out of four patients achieving a complete response This approval marks the third indication for EPKINLY and the first-ever FDA approval for a bispecific combination therapy in the lymphoma spaceCOPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult...

Havila Kystruten AS (“Havila Kystruten” or the “Company”) has today entered into a comprehensive refinancing of its outstanding debt totalling EUR 456 million. The transaction is expected to close by 25 November 2025, subject to customary closing conditions. The transaction provides the Company with a 15-year financing, providing stability and flexibility to the Company, while also containing flexibility for potential refinancing during the facility period. The new EUR equivalent 456 million facility refinances approximately EUR 331 million of senior secured bonds, including accrued interest and call premiums, and approximately EUR 116 million of unsecured shareholder loans. It provides around EUR 4 million in additional liquidity to the Company net of transaction fees. This refinancing significantly reduces the Company’s effective interest...

Scott recognized for improving patient care and advancing innovation in workers’ compensation at CorVel FORT WORTH, Texas, Nov. 18, 2025 (GLOBE NEWSWIRE) — CorVel Corporation is proud to announce that Sarah Scott, Executive Vice President of Product and Corporate Services, has been named to Business Insurance’s prestigious “Women to Watch” list for 2025. Now celebrating its 20th year, the award honors women who have achieved extraordinary success in insurance and risk management through leadership, innovation, and mentorship. A 26-year veteran of CorVel, Scott has played a pivotal role in advancing the Company’s product innovation, clinical integration, and digital transformation initiatives. In her current role, she oversees the development and evolution of CorVel’s entire product portfolio, ensuring the organization continues...

Submit Your Vote in Advance of November 25, 2025, Annual Meeting Visit VoteWKHS.com for Information on How to Vote CINCINNATI, Nov. 18, 2025 (GLOBE NEWSWIRE) — Workhorse Group, Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reminded Workhorse shareholders to vote FOR its transaction with Motiv, as well as the other proposals, in connection with the upcoming 2025 Annual General Meeting of Shareholders (the “Annual Meeting”). Shareholders of record as of the close of business on September 18, 2025, are entitled to vote in connection with the Annual Meeting, which is scheduled for November 25, 2025. Shareholders who have not already submitted their vote are encouraged to do so before the Annual Meeting, and can visit...